PubMed:11773892 / 1827-2026 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"441","span":{"begin":121,"end":129},"obj":"OrganismTaxon"},{"id":"442","span":{"begin":138,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A38","pred":"db_id","subj":"441","obj":"NCBITaxon:9606"},{"id":"A39","pred":"db_id","subj":"442","obj":"MESH:D007676"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin-sentences","denotations":[{"id":"T17","span":{"begin":0,"end":199},"obj":"Sentence"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T22","span":{"begin":26,"end":30},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":92,"end":96},"obj":"GeneOrGeneProduct"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T23","span":{"begin":138,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A23","pred":"originalLabel","subj":"T23","obj":"D007676"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T19","span":{"begin":138,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A19","pred":"mondo_id","subj":"T19","obj":"0004375"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T23","span":{"begin":138,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A23","pred":"ID:","subj":"T23","obj":"D007676"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T23","span":{"begin":138,"end":142},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A23","pred":"#label","subj":"T23","obj":"D007676"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T7","span":{"begin":121,"end":129},"obj":"OrganismTaxon"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T23","span":{"begin":138,"end":142},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T17568","span":{"begin":121,"end":129},"obj":"OrganismTaxon"}],"attributes":[{"id":"A23","pred":"#label","subj":"T23","obj":"D007676"}],"text":"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group."}